肾透明细胞癌 (KIRC) 是肾癌的主要形式，对免疫检查点抑制剂 (ICIs) 表现出多种治疗反应，凸显了对 ICI 疗效预测模型的需求。我们的研究构建了一个基于 13 种类型的程序性细胞死亡 (PCD) 的预后模型，这些细胞死亡与肿瘤进展和免疫微环境交织在一起。通过对综合数据集的分析进行验证，该模型确定了七个关键的 PCD 基因，这些基因描绘了具有不同免疫特征和对抗 PD-1 治疗敏感性的两种亚型。高 PCD 组表现出更强的免疫抑制环境，而低 PCD 组对 PD-1 治疗表现出更好的反应。特别是，TOP2A 变得至关重要，它的抑制显着降低 KIRC 细胞的生长和迁移率。这些发现强调了 PCD 在预测 KIRC 结果和免疫治疗反应方面的相关性，对增强临床决策具有影响。© 2024。作者。

Kidney Clear Cell Carcinoma (KIRC), the predominant form of kidney cancer, exhibits a diverse therapeutic response to Immune Checkpoint Inhibitors (ICIs), highlighting the need for predictive models of ICI efficacy. Our study has constructed a prognostic model based on 13 types of Programmed Cell Death (PCD), which are intertwined with tumor progression and the immune microenvironment. Validated by analyses of comprehensive datasets, this model identifies seven key PCD genes that delineate two subtypes with distinct immune profiles and sensitivities to anti-PD-1 therapy. The high-PCD group demonstrates a more immune-suppressive environment, while the low-PCD group shows better responses to PD-1 treatment. In particular, TOP2A emerged as crucial, with its inhibition markedly reducing KIRC cell growth and mobility. These findings underscore the relevance of PCDs in predicting KIRC outcomes and immunotherapy response, with implications for enhancing clinical decision-making.© 2024. The Author(s).